#1 Clinical Trials Search in Europe

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

3 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The study will evaluate the effectiveness of different treatment combinations. The treatments being studied include bortezomib (known as Velcade), melphalan, prednisone, lenalidomide, dexamethasone, carfilzomib, and daratumumab. These medications are used in various combinations to see which works best for patients who are newly diagnosed with multiple myeloma and are between 65 and 80 years old.

The purpose of the study is to compare the effectiveness of these treatments in achieving a complete response, which means the cancer is no longer detectable. Participants will receive one of the treatment combinations for a period of 18 cycles, followed by additional treatment to maintain the response. Some participants will receive a placebo to help researchers understand the true effect of the medications. The study will last several years, with regular check-ups to monitor the participants’ health and the progress of the disease.

Throughout the study, participants will be closely monitored to ensure their safety and to track the effectiveness of the treatments. The study aims to find the best treatment approach for older adults with multiple myeloma, improving their chances of a better outcome and quality of life. Participants will receive care from a team of healthcare professionals who specialize in treating multiple myeloma.

1 joining the study

Upon joining the study, you will be randomly assigned to one of the treatment groups. This means you will receive one of the different treatment combinations being tested.

2 induction therapy

The induction therapy phase lasts for 18 cycles. During this time, you will receive a combination of medications depending on your assigned group.

If you are in the control group, you will receive bortezomib (subcutaneous injection), melphalan (oral), and prednisone (oral).

If you are in the experimental group, you will receive carfilzomib (intravenous), lenalidomide (oral), and dexamethasone (oral), with or without daratumumab (subcutaneous injection).

3 midway evaluation

After 9 cycles of induction therapy, an evaluation will be conducted to assess your response to the treatment. This involves checking the levels of certain proteins in your blood.

4 end of induction evaluation

At the end of the 18 cycles of induction therapy, another evaluation will be conducted to determine the effectiveness of the treatment.

5 consolidation therapy

Following the induction phase, you will enter the consolidation therapy phase. This phase aims to strengthen the response achieved during induction.

6 maintenance therapy

After consolidation, you will begin maintenance therapy. This phase involves taking lenalidomide (oral) and possibly daratumumab (subcutaneous injection) to maintain the response to treatment.

Maintenance therapy will continue for at least five years, with regular evaluations to monitor your health and response to the treatment.

7 regular evaluations

Throughout the trial, regular evaluations will be conducted to monitor your health, the effectiveness of the treatment, and any side effects you may experience.

Who Can Join the Study?

  • Patients must have been newly diagnosed with multiple myeloma and need to start treatment.
  • The heart’s left ventricle must be working at 40% or better. This is called the left ventricle ejection fraction.
  • Male patients taking the drug lenalidomide must use condoms during sexual activity with women who are pregnant or could become pregnant, even if they have had a vasectomy. Alternatively, they must agree to total abstinence. This must continue during treatment and for at least 30 days after treatment ends. They must also agree not to donate sperm during treatment and for at least 90 days after treatment ends.
  • Patients must be between 65 and 80 years old.
  • Patients should be in good overall health, as measured by a health status scale. A score of 42 or less on this scale is required.
  • Patients must sign an informed consent form, agreeing to participate in the study.
  • Patients must have a measurable disease. This means:
    • For secretory multiple myeloma, there must be a certain level of a protein called M-protein in the blood or a certain amount of free light chains in the urine.
    • For oligo-secretory or non-secretory multiple myeloma, the level of free light chains in the blood must be at a certain level with an abnormal ratio.
  • Patients must have a functional status of 2 or less, as defined by a specific scale used to measure daily living abilities.
  • Patients must have a life expectancy of more than 3 months.
  • Patients must have adequate organ function, which includes:
    • A certain level of platelets, hemoglobin, and neutrophils in the blood.
    • Liver enzymes (AST and ALT) must not be more than 2.5 times the normal limit.
    • Total bilirubin must not be more than 2 times the normal limit.
    • Serum creatinine must be 2 mg/dl or less.
    • Calcium levels must be 14 mg/dl or less, even if albumin levels are not normal.
  • The investigator must believe that the patient can follow all the study requirements.

Who Cannot Join the Study?

  • Patients who have a different type of cancer other than multiple myeloma.
  • Patients who are eligible for a bone marrow transplant. This is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells.
  • Patients who are not in good general health. This means that the patient should not have other serious health problems that could affect the study.
  • Patients who are part of a vulnerable population. This includes groups of people who may need special protection, such as children, pregnant women, or those unable to make decisions for themselves.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario Y Politecnico La Fe Valencia Spain
Hospital Universitario Hm Sanchinarro Madrid Spain
Hospital Universitario De Navarra Pamplona Spain
Hospital Universitario De Salamanca Salamanca Spain
Hospital Jerez de la Frontera Jerez De La Frontera Spain

Other Sites

Site Name City Country Status
Hospital General Universitario Gregorio Maranon Madrid Spain
Hospital Universitario 12 De Octubre Madrid Spain
Hospital General Universitario Morales Meseguer Murcia Spain
Hospital Universitario Infanta Leonor Madrid Spain
Hospital Clinico Universitario Lozano Blesa Zaragoza Spain
Complexo Hospitalario Universitario De Pontevedra Pontevedra Spain
Hospital Universitario Dr Peset Aleixandre Valencia Spain
Hospital Universitari Joan XXIII De Tarragona Tarragona Spain
El Hospital Universitario De Gran Canaria Dr. Negrin Las Palmas De Gran Canaria Spain
Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada Manresa Spain
Hospital General Universitario De Albacete Albacete Spain
Virgen del Rocío University Hospital Sevilla Spain
Hospital Clinic De Barcelona Barcelona Spain
Hospital Universitario De Cruces Barakaldo Spain
Hospital Universitario Fundacion Jimenez Diaz Madrid Spain
Hospital Universitario De Leon Leon Spain
University Clinical Hospital Virgen De La Arrixaca Murcia Spain
Universidade De Santiago De Compostela Santiago De Compostela Spain
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida Lleida Spain
Hospital Son Llatzer Palma Spain
Hospital Universitario Araba Vitoria Spain
Hospital Universitario Virgen De Valme Sevilla Spain
Hospital Universitari De Girona Doctor Josep Trueta Girona Spain
Hospital Universitario Lucus Augusti Lugo Spain
Hospital Universitario De Canarias La Laguna Spain
Servei De Salut De Les Illes Balears Palma Spain
Hospital Costa del Sol Marbella Spain
Hospital Universitario Virgen De La Victoria Malaga Spain
Hmfnvvqz Urfjogzgwcckx Dl Lc Pymlvrup Madrid Spain
Htzmzdwd Uhnvcmiyjotqi Mwmhvqs Dh Vyjtzxtfot Santander Spain
Izeidfuc Crqvvu Dicbvszevrgehbyvh L'hospitalet De Llobregat Spain
Cboutnpd Hdmomfdxccsn Ueozccpzhuodg Dl Voqi Vigo Spain
Hdazqphl Ukorklybvzqpr Dzlnsqqo Donostia / San Sebastian Spain
Hhfjybrl Dk Lh Sjgoc Cfps I Spju Pzg Barcelona Spain
Fhicangvm Plux Lk Ifbzhsneghdmf Bdcudubkc Din Hftcuxyh Umiocwvduchzd Lv Peo Madrid Spain
Hwvzsouz Udaztnhjzwbvs Hiftincl Tmkuf y Pdphon Iidmhxjo Cisjou dfmujyybpsvtpmvas (erip Badalona Spain
Hhmkbdis Vzyv dltgqlos Barcelona Spain
Hjdavvcw Unkfwqsboyvnu df A Cozuyc A Coruna Galicia Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
22.10.2018

Trial locations

Investigated drugs:

Bortezomib is a medication used to treat multiple myeloma, a type of blood cancer. It works by blocking certain proteins in cancer cells, which helps to slow down or stop their growth. In this trial, it is part of the initial treatment phase to help reduce the number of cancer cells in the body.

Melphalan is a chemotherapy drug that is used to treat multiple myeloma. It works by damaging the DNA of cancer cells, which prevents them from multiplying. This helps to control the spread of the disease and reduce symptoms.

Prednisone is a type of steroid that is used to help reduce inflammation and suppress the immune system. In the context of multiple myeloma, it is used to help manage symptoms and improve the effectiveness of other cancer treatments.

Lenalidomide is a medication that helps the immune system fight cancer. It works by slowing the growth of cancer cells and helping the body’s immune system attack them. It is used in this trial as part of both the initial and maintenance treatment phases.

Dexamethasone is a steroid that helps reduce inflammation and is used to treat various conditions, including multiple myeloma. It is often used in combination with other cancer treatments to help improve their effectiveness and manage side effects.

Carfilzomib is a medication used to treat multiple myeloma. It works by blocking certain proteins in cancer cells, which helps to stop their growth and spread. It is part of the experimental treatment being tested in this trial.

Daratumumab is a type of targeted therapy known as a monoclonal antibody. It works by attaching to a specific protein on the surface of cancer cells, helping the immune system to recognize and destroy them. It is being tested in combination with other treatments in this trial to see if it improves outcomes for patients with multiple myeloma.

Multiple myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and crowd out healthy blood cells, leading to bone damage, anemia, and increased risk of infections. As the disease progresses, it can cause bone pain, fractures, and kidney problems due to the accumulation of abnormal proteins produced by the cancerous cells. Over time, the disease can lead to significant bone loss and damage to other organs. The progression of multiple myeloma is typically slow, but it can vary greatly between individuals. The disease is characterized by periods of stability and periods of active disease, where symptoms become more pronounced.

Trial ID:
2024-516905-22-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1 1
    Investigated drugs:
    Norway